This project aims to establish and prospectively register a longitudinal, multimodal biobank for primary central nervous system lymphoma (PCNSL). The study will primarily enroll patients undergoing needle biopsy or surgical resection of lesions involving the brain, spinal cord, or meninges, with a pathological diagnosis of central nervous system lymphoma. To ensure population homogeneity, patients with PCNSL will constitute the core analysis cohort. Patients with imaging findings suggestive of PCNSL but a final pathological diagnosis other than PCNSL will serve as disease controls, and matched healthy volunteers will be recruited as baseline controls. At baseline, biopsy tissue, cerebrospinal fluid (CSF), peripheral blood, urine, saliva, and stool samples will be collected. Follow-up visits will be scheduled at 1 month after biopsy and every 3-6 months thereafter, with contrast-enhanced brain magnetic resonance imaging (MRI) and serial collection of CSF and peripheral blood. After the requirements of routine pathological diagnosis have been met, biopsy specimens will undergo tiered multi-omics profiling according to sample availability and freshness, including whole-exome sequencing, bulk RNA sequencing, single-cell RNA sequencing, metabolomics, spatial transcriptomics, and spatial metabolomics. Analyses of CSF and blood samples will focus on circulating tumor DNA and cell-free RNA (ctDNA/cfRNA), supplemented by conventional cytology, flow cytometry, and other clinical data for longitudinal disease monitoring. The project will develop an integrated database incorporating clinical, imaging, pathological, molecular, and biospecimen data. It will characterize the relationships of baseline tissue multi-omics features and longitudinal changes in CSF- and blood-derived ctDNA/cfRNA with treatment response, recurrence prediction, and prognosis. The study will also develop diagnostic and risk-stratification models applicable to patients at our institution, across the region, and potentially throughout mainland China, while establishing standardized operating procedures for biospecimen collection and processing. This work is expected to provide high-quality evidence and a sustainable translational research platform for elucidating the biological heterogeneity of PCNSL, validating liquid-biopsy biomarkers, and optimizing precision follow-up strategies.
Study Type
OBSERVATIONAL
Enrollment
400
Standard-of-care treatment containing high-dose methotrexate as the backbone regimen, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. Treatment selection, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.
Standard-of-care treatment containing a Bruton tyrosine kinase inhibitor as a principal therapeutic component, administered alone or in combination with other anticancer agents according to the treating physician's judgment and institutional practice. The specific BTK inhibitor, dose, schedule, combination regimen, and duration are not assigned by the study protocol. Clinical response, recurrence, survival, adverse events, imaging findings, and longitudinal molecular biomarkers will be recorded prospectively.
Deparment of neurosurgery, Beijing tiantan hospital
Beijing, Beijing Municipality, China
Deparment of neurosurgery, Shandong Provincial Hospital
Shandong, Jinan, China
Deparment of neurosurgery, Tianjin huanhu hospital
Tianjin, Tianjin Municipality, China
Baseline data completeness rate
Percentage of enrolled participants with complete required baseline clinical, imaging, pathological, treatment, and biospecimen information in the electronic case report form. The numerator is the number of participants with all protocol-required baseline data; the denominator is the total number of enrolled participants.
Time frame: At baseline, from enrollment through completion of baseline assessments(up to 30 months)
Paired tumor tissue and cerebrospinal fluid sample acquisition rate
Percentage of eligible participants from whom both evaluable tumor tissue and cerebrospinal fluid samples are successfully collected and stored according to the study standard operating procedures.
Time frame: within 1 month after biopsy or surgery (up to 30 months)
Participant follow-up completion rate
Percentage of enrolled participants who complete the protocol-required clinical and imaging follow-up assessments at Month 12 and Month 24. Completion rates will be calculated separately for each time point.
Time frame: from enrollment to follow-up at Month 3, 6, 12, 24 and 36 (up to 36 months)
Adherence to longitudinal cerebrospinal fluid sampling
Percentage of scheduled cerebrospinal fluid collection visits completed among participants enrolled in the longitudinal cerebrospinal fluid/peripheral blood subcohort.
Time frame: Postoperative Month 1 and every 3-6 months thereafter (up to 36 months)
Association between cerebrospinal fluid ctDNA clearance and MRI response
Cerebrospinal fluid circulating tumor DNA status will be classified as cleared or not cleared at postoperative Month 3 and compared with concurrent MRI response categories-complete response, partial response, stable disease, or progressive disease. The association or agreement will be assessed using contingency-table analysis, kappa statistics, and/or receiver operating characteristic analysis, as applicable.
Time frame: 3-6 months after pathological comfirmation (up to 36 months)
Association of baseline and longitudinal ctDNA/cfRNA status with progression-free survival
Progression-free survival will be evaluated according to baseline and longitudinal cerebrospinal fluid or peripheral blood ctDNA/cfRNA status. Progression-free survival is the time from the prespecified index date to radiographic or clinical disease progression or death from any cause, whichever occurs first.
Time frame: From the prespecified index date through Month 3, 6, 12, 24 and 36 (up to 36 months)
Objective response rate
Percentage of evaluable participants achieving complete response or partial response on MRI, summarized according to prespecified baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Best overall response
Best MRI response recorded during follow-up-complete response, partial response, stable disease, or progressive disease-summarized according to baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Progression-free survival
Time from the prespecified index date to radiographic or clinical progression or death from any cause, whichever occurs first, analyzed according to baseline tumor multi-omics characteristics.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Overall survival
Time from the prespecified index date to death from any cause. Participants without a documented death will be censored at the date they were last known to be alive.
Time frame: From treatment initiation to follow-up at month 3,6,12,24 and 36 (up to 36 months)
Lead time from molecular recurrence detected by cerebrospinal fluid ctDNA to radiographic recurrence
Number of days between the first post-clearance cerebrospinal fluid ctDNA reappearance or prespecified increase in variant allele fraction and the date of MRI-confirmed disease recurrence. Positive values indicate that molecular recurrence preceded radiographic recurrence.
Time frame: Postoperative Month 1 and every 3 months thereafter (up to 36 months)
Concordance and clinical associations of key driver variants in tumor tissue and cerebrospinal fluid
Concordance of key driver variants, including MYD88, between tumor tissue and cerebrospinal fluid ctDNA, and their associations with pathological subtype, treatment regimen, response, progression, and survival.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At baseline and every 3-6 months after pathological confirmation (up to 36 months)
Molecular evolution between diagnosis and recurrence
Changes in somatic variants, variant allele fractions, copy-number alterations, transcriptomic features, or other prespecified molecular characteristics between paired diagnostic and recurrence samples.
Time frame: From baseline to the first documented recurrence (up to 36 months)
Change in neurological and performance status
Change from baseline in neurological function and performance status, including Karnofsky Performance Status and/or Eastern Cooperative Oncology Group performance status.
Time frame: At baseline and every 3-6 months thereafter (up to 60 months)
Change in cognitive function
Change from baseline in cognitive function measured using a prespecified validated cognitive assessment instrument.
Time frame: At baseline and every 3 months thereafter (up to 60 months)
Incidence of treatment-related adverse events
Number and percentage of participants experiencing treatment-related adverse events, summarized by event type, severity, and relationship to treatment using a prespecified adverse-event grading system.
Time frame: From enrollment to follow-up (up to 36 months)